Newron Pharmaceuticals SpA operates as a biopharmaceutical company. The company is headquartered in Bresso, Milano and currently employs 22 full-time employees. The company went IPO on 2006-12-12. The company focuses on the discovery and development of pharmaceutical products. The firm is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The firm undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Follow-Up Questions
Newron Pharmaceuticals SpA 'in CEO'su kimdir?
Prof. Stefan Weber 2005 'den beri şirketle birlikte olan Newron Pharmaceuticals SpA 'in Chief Executive Officer 'ıdır.
NWPHF hissesinin fiyat performansı nasıl?
NWPHF 'in mevcut fiyatı $0 'dir, son işlem günde 0% decreased etti.
Newron Pharmaceuticals SpA için ana iş temaları veya sektörler nelerdir?
Newron Pharmaceuticals SpA Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 5 analist Newron Pharmaceuticals SpA için analist derecelendirmeleri gerçekleştirdi, bunlar 3 güçlü al, 4 al, 1 tut, 0 sat ve 3 güçlü sat içermektedir
